comova

I believe this is to improve performance by shortening the context window for long thinking processes. I don't think this is referring to real-time summarizing for the users' sake.

For example, in the recent Phase 2b CB1 agonist for cannabis user disorder from AELIS, the FDA required a standard of efficacy of an 80% reduction in use. The trial failed for unrelated reasons, but many researchers in the field have expressed frustration that this requirement, a reduction far beyond what will improve a patient’s health, sends a negative signal to other companies interested in advancing effective addiction treatments.

I’ve lost 60 pounds and my health has improved considerably. I was overeating out of boredom and stress. I’ve been able to reduce my blood pressure medication. My blood sugar is much more controlled. I started riding a recumbent bike for an hour and a half a day due to concerns of losing muscle along with fat.

yes

A new, large retrospective study of patient health records shows a 40% drop in opioid overdoses and a 50% drop in cases of alcohol intoxication among people who received GLP-1RAs (typically for diabetes or obesity).

And if you haven't asked a friend who's on one, taking a GLP-1 medication reduces drinking by about 50%:

https://recursiveadaptation.com/p/first-ever-randomized-tria...

"These findings provide compelling evidence that acute alcohol consumption decreases GLP-1, a satiation signal, elucidating alcohol's 'apéritif' effect." This could increase hunger and cravings (including for more alcohol).

“I’m now offering GLP-1s to nearly all my substance use disorder patients.”

This shape, known since at least Plato's time and named by Kepler, has fascinated thinkers from Archimedes to Buckminster Fuller. As its name implies, it's somewhere between a cube and an octahedron, taking six and eight of its 14 sides from each of those respectively. It's rounder than either of those shapes though, making it a much better vessel for salt, olives, or weed.

"Because the pharma companies with approved GLP-1s do not pursue addiction treatment, a large scale trial and FDA indication will not happen on its own. Without a strategic public effort along these lines, we may be waiting 10-15 years before a GLP-1 indication becomes available.

If we are successful in launching large-scale studies, this will be an unprecedented non-profit scientific endeavor, filling the gap between public research agencies and pharma, and collaborating with both along the way. We’re excited."

If you're interested in the addiction side of this, I write the substack that Scott links to in this post. Here's the article he links to:

https://recursiveadaptation.com/p/the-growing-scientific-cas...

I think that studies of GLP-1RAs for alcohol and opioid addiction are the biggest public health opportunities in the world right now, in terms of leverage and scale.

GLP-1 Rapid Access Care (GRACE) is a proposed model of opioid harm reduction that would provide immediate access to GLP-1RA craving reduction treatment for people with OUD without the obstacles to initiation of opioid agonist therapy (OAT) and without requiring abstinence. GRACE can bridge harm reduction and treatment and can be deployed in settings where medication for opioid use disorder (MOUD) treatment initiation has not traditionally been possible.

Smoking causes more deaths than any other substance use disorder. In the US, 480,000 people die annually from smoking-related causes.

A new real-world retrospective cohort study using electronic health records from TriNetX shows a 28% reduction in nicotine use disorder for patients taking semaglutide (Ozempic) vs other diabetes medications.

We also have a history of vaccines and antibiotics, so I don't think we should automatically assume there's some deep risk. These have been on the market for over a decade now and used by tens of millions of people.

They will be coming in a few months when it gets published. They showed numbers at the conference but did not want them reported.

History of medicine is full of incredible breakthroughs that are mostly upsides, like antibiotics, vaccines, new cancer immune therapies, etc. It happens!

Hi-- this is my article! It's becoming clear that there's a revolution about to happen in addiction treatment through GLP-1s and it might be the first time we get a big positive impact on deaths from alcohol and opioids. Please subscribe to our substack!

1. GLP-1 drugs appear to dramatically reduce addictive drive across substances. 2. GLP-1 drugs can reach vastly more patients than existing medications and they have positive mental health benefits for anxiety and depression. 3. This is our first ever opportunity to make a big dent in the addiction crisis, which kills 770,000 people a year between opioids, cigarettes, and alcohol.

hi! this is my substack post and new policy org. thanks to whoever posted this. hope you will subscribe!

we are looking for folks with MDs and PhDs or other experience in the field or in EA type writing to join the project. the thesis is that the addiction crisis is solvable if we put sufficient resources into new medication development, including GLP-1 for addiction and powerful non opiate painkillers like the Vertex drug that will be approved early next year.

addiction is the number 1 cause of DALYs in the united states if you include opiates, stimulants, alcohol, and cigarettes.

the right policies can get new treatments to people rapidly without massive public costs and without disrupting incentives. but we're currently on track for at least another decade of massive damage if we don't change things. join the effort!

can you explain more about how realistic this type of conversion actually is? has it been attempted at any level? @aimonster2

incredible concept and really well built. so many hard problems being tackled here!